GLP-1 Skin Changes: What Ozempic, Wegovy, Mounjaro and Zepbound Do to Your Skin

Q: Does Ozempic make your skin dry?

The American Academy of Dermatology (AAD) lists dry skin among the effects GLP-1 users report and links it to hormone changes and to eating and drinking water less often. No study has measured skin dryness in people taking semaglutide, so how common it is remains unknown. The AAD suggests a gentle cleanser, a ceramide moisturizer applied to damp skin and a humidifier.

Q: Why does my skin itch on Mounjaro or Zepbound?

Itching can be part of a hypersensitivity or injection-site reaction. On the Zepbound label, hypersensitivity reactions affected 5% of people at each dose vs 3% on placebo, and most were skin reactions such as rash and itching. Burning or tingling without a rash matches dysesthesia, listed at 0.2% to 0.4% on tirzepatide. Tell your prescriber about any reaction that persists or spreads.

Q: Can GLP-1 drugs cause acne?

The AAD lists acne breakouts due to hormone changes among effects patients report. A 2024 meta-analysis covering 45 articles on 6 GLP-1 drugs found no conclusive acne side effects. Its authors suggested that hormonal changes from weight loss may explain the acne some users report, but that idea is their hypothesis, not a tested finding.

Q: Does GLP-1 skincare actually work?

No product sold as GLP-1 skincare contains a GLP-1 drug. As of October 2026, 2 small, industry-linked studies have tested topicals in GLP-1 users, with 33 and 25 participants over 12 weeks. No peptide product has been tested in this group.

Q: Should I use retinol while on a GLP-1?

The AAD says GLP-1 users can consider retinoids, but if skin is dry they may cause irritation and flaking. No study has tested retinol or other retinoids in GLP-1 users. A dermatologist can help decide whether a retinoid suits your skin.

Q: What body wash or cleanser helps dry skin on a GLP-1?

No specific body wash or cleanser has been tested in GLP-1 users. The AAD recommends a gentle cleanser followed by a moisturizer with ceramides and antioxidants, applied to damp skin over the whole body, including the cuticles.

Q: Does GLP-1 help psoriasis?

The evidence is mixed. Small semaglutide studies and a tirzepatide-plus-biologic trial found psoriasis improvements, while an 8-week liraglutide trial found no significant change and a large diabetes cohort linked GLP-1 drugs to more new psoriasis cases than a comparison drug.

Q: Will loose skin tighten back up after GLP-1 weight loss?

No study has tracked whether skin or facial volume recovers after GLP-1 weight loss. Cleveland Clinic says Ozempic face won't fade with time if the weight loss is maintained. The only facial measurement found midface volume fell about 7% per 10 kg lost in 20 people.

Q: Is GLP-1 hair loss permanent?

The Wegovy and Zepbound labels describe hair loss as associated with weight reduction, and a review describes it mainly as telogen effluvium, a shedding pattern linked to rapid weight loss. No study in our sources tracked how long it lasts after weight stabilizes.

By Peptide Skincare Editorial Team · Published October 25, 2026 · Updated October 18, 2026 · 21 min read

Start with our pillar guide: How to Fix Ozempic Face: What the Evidence Supports (2026), or browse all GLP-1 & Skin articles.

GLP-1 skin changes from Ozempic, Wegovy, Mounjaro and Zepbound fall into 3 buckets. Drug reactions, such as injection-site reactions, rash and skin pain, are measured in label trials. Weight-loss-driven changes, such as facial volume loss and dryness, rest on one small study and expert reports. Psoriasis and hidradenitis improvements are mixed or early. Evidence: Limited.

Never stop, skip or change a GLP-1 medication for skincare reasons. Talk to your prescriber first.

This is our hub page for GLP-1 skin questions. Each section gives a short answer and links to the deeper guide. For facial changes, start with our pillar guide on how to fix Ozempic face, then see Wegovy face before and after and Mounjaro face. For FDA adverse event reports, see our analysis of GLP-1 skin and hair side effects in FDA data.

GLP-1 receptor agonists mimic a gut hormone that reduces appetite. Semaglutide is sold as Ozempic and Wegovy, and tirzepatide as Mounjaro and Zepbound. In the US, Zepbound is the weight-management brand of tirzepatide, and Mounjaro is approved for type 2 diabetes, not weight loss. In the UK, Mounjaro is the brand name used for weight management.

Key takeaways

On the Zepbound label, injection-site reactions affected 6% to 8% of people vs 2% on placebo, and a systematic review of 9 RCTs linked 10 and 15 mg tirzepatide to more of them than 5 mg (Meng et al., 2023).
The June 2026 Wegovy label lists skin pain or burning (dysesthesia) in 22% of people on 7.2 mg, 6% on 2.4 mg and 0% on placebo.
In a 20-person CT/MRI study, midface volume fell about 7% per 10 kg of weight lost (Sharma et al., 2025). No study has measured GLP-1 dry skin.
No "GLP-1 skincare" product contains the drug. Two small, industry-linked topical studies in GLP-1 users exist, with 33 and 25 participants (Nguyen et al., 2026; Moradi et al., 2026).
Psoriasis results disagree: small trials improved, while a cohort of 169,630 people per group linked GLP-1 drugs to more new psoriasis (Chiang et al., 2026).

What does GLP-1 do to your skin?

GLP-1 drugs affect skin in 3 ways: reactions to the drug itself, changes driven by weight loss, and possible improvement in inflammatory skin disease. The evidence behind each bucket is very different, so sorting a symptom into its bucket tells you how much is known about it.

GLP-1 skin changes in 3 buckets, with evidence labels
Feature	What falls here	Evidence label and best sources
Drug reactions	Injection-site reactions; rash, itching, hives; skin pain or burning (dysesthesia); excessive sweating as a reporting signal	Moderate. Label trials (Zepbound, Wegovy) and STEP UP; tirzepatide dose link from a systematic review of 9 RCTs
Weight-loss-driven changes	Facial volume loss; loose skin on face, neck and body; hair shedding; dry skin	Early / preliminary for faces (one 20-person imaging study); Moderate for hair loss rates (Cheng 2026); no measured data for dryness (AAD explanation only)
Disease improvement	Psoriasis; hidradenitis suppurativa (HS)	Mixed / contested. Small trials improved; a large cohort points the other way; an HS cohort found similar declines in non-users

Bottom line: Acne doesn't fit neatly: the AAD links it to hormone changes, while a 2024 meta-analysis found no conclusive acne side effects. Evidence: Limited.

A 2026 dermatology review summed up the field: GLP-1 skin evidence is "strongest for mechanistic plausibility and observational clinical signals, whereas dermatology-specific randomized trials remain limited" (Vyas et al., 2026). The sections below take each bucket in turn. Evidence: Limited.

Do GLP-1 injections cause skin reactions?

Yes, in a minority of people, and for tirzepatide the rate rises with dose. Injection-site reactions, rash and itching are the best-documented GLP-1 skin effects because they were counted in placebo-controlled trials.

In pooled SURMOUNT-1 and SURMOUNT-2 data on the Zepbound label, injection-site reactions affected 6%, 8% and 8% at 5, 10 and 15 mg vs 2% on placebo. Hypersensitivity reactions affected 5% at each dose vs 3%, and "the majority of the hypersensitivity reactions in trials were skin reactions (e.g., rash, itching)." The Mounjaro label reports hypersensitivity in 3.2% vs 1.7%, "sometimes severe (e.g., urticaria and eczema)."

A systematic review of 9 tirzepatide RCTs with 9,818 patients found more injection-site reactions at 10 and 15 mg than at 5 mg (P<0.01) (Meng et al., 2023). Antibodies may play a part. Across 7 SURPASS diabetes trials (n=5,025), 51.1% developed antidrug antibodies, and more antibody-positive patients had hypersensitivity or injection-site reactions, mostly nonserious (Mullins et al., 2024); all authors were Eli Lilly employees. The Zepbound label shows the same pattern: 11.3% with anti-tirzepatide antibodies vs 1% without.

The AAD lists itch, rash and swelling at the injection site among reported effects, and says to ask the prescribing doctor for injection tips if irritation doesn't improve. Rare severe events exist (El-Amawy et al., 2026). A systematic review of 80 studies listed panniculitis (fat inflammation), bullous pemphigoid, lupus and vasculitis, while finding most skin reactions mild to moderate and reversible; underreporting limits estimates (Ho et al., 2026).

Skin pain or burning with no rash

A recurring question in GLP-1 communities describes a sunburn-like feeling with no rash after injections. That matches dysesthesia, an abnormal, often unpleasant skin sensation. The Wegovy label groups burning sensation, pain of skin, paresthesia, sensitive skin and similar terms under that heading, and states that "the incidence of dysesthesia with WEGOVY increased with increasing dosage."

Dysesthesia rates on GLP-1 drug labels Source: Wegovy label (06/2026, 7.2 mg trial), Zepbound and Mounjaro labels (08/2026). Different trials; compare with care.

Show data table

Drug and group	% with dysesthesia
Wegovy trial: placebo (n=303)	0%
Wegovy 2.4 mg (n=304)	6%
Wegovy 7.2 mg (n=1,311)	22%
Zepbound placebo	0.1%
Zepbound 15 mg	0.4%
Mounjaro (each dose)	0.4%

STEP UP, a 72-week phase 3b RCT of 1,407 adults sponsored by Novo Nordisk, reported dysaesthesia (British spelling) in 22.9% on 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo (Wharton et al., 2025). Tirzepatide labels list 0.2% to 0.4%. Our Mounjaro skin sensitivity guide covers when to call a doctor, and Zepbound skin side effects has drug-specific detail.

What FDA adverse event reports add

FDA Adverse Event Reporting System (FAERS) studies add signals, not rates. FAERS reports show what patients and clinicians reported while on a drug. They don't show that the drug caused the event, and they can't be used to estimate how often it happens.

A FAERS analysis of semaglutide, liraglutide, exenatide and dulaglutide from 2018 to 2024 (tirzepatide wasn't included) found skin events in up to 8.16% of GLP-1 reports, proportionally less often than for DPP-4 inhibitors, another diabetes drug class (proportional reporting ratio 0.27). Semaglutide had the highest rate and dulaglutide the lowest (Fat et al., 2026). For tirzepatide, injection-site reactions were among the strongest signals (Guo et al., 2026), and an earlier analysis flagged injection-site hemorrhage as a new signal, with women reporting more injection-site reactions (Chen et al., 2025).

Most tirzepatide adverse-event reports describe onset in the first month (signal data, not incidence)

Day 13
Median onset (Guo 2026)
Median time to onset in a 2026 tirzepatide FAERS analysis, where injection-site reactions were among the strongest signals.
Day 23
Median onset (Chen 2025)
Median onset in an earlier tirzepatide FAERS analysis, which flagged injection-site hemorrhage (bleeding at the site) as a new signal.
Day 30
67.1% of reports with onset data
By 30 days, 67.1% of reported events with a valid onset date had begun. This figure covers all adverse events, not only skin or injection-site reactions.

Our FDA data analysis covers report trends in depth. Evidence: Moderate (label trials and a systematic review); FAERS findings are signals only.

Why does GLP-1 skin get dry on Ozempic, Wegovy or Zepbound?

The AAD attributes GLP-1 dry skin to "hormone changes and eating and drinking water less often" (AAD). No study has measured skin hydration or dryness in GLP-1 users, so that explanation is expert opinion, not a tested finding.

A recurring reader question describes dry skin, chapped lips or peeling around months 3 to 4, even with plenty of water. A 2026 systematic review of 40 mixed studies, including case reports, listed poor hydration and insufficient protein among possible risk factors for skin changes during GLP-1 weight loss, but didn't quantify them (Barone et al., 2026). A narrative review estimated that about 22.4% of GLP-1 patients have at least 1 documented nutritional deficiency within a year, including vitamin D deficiency in 13.6% at 12 months, and said deficiencies "may plausibly compound" skin changes (Karlin et al., 2026).

The AAD's tips for dry skin are in the routine below. Our skin barrier basics explains how ceramides and occlusives work in general. Evidence: Early / preliminary.

Does GLP-1 cause loose skin and "Ozempic face"?

Faces lose volume roughly in line with weight lost, but only one small study has measured it. In a retrospective cohort of 20 people with CT or MRI scans a mean 321 days apart, median midface volume fell 9.0% after a mean 11.0 kg loss, about 7% per 10 kg, with superficial fat down 11% and deep fat 7%; funding wasn't reported and results weren't broken out by drug (Sharma et al., 2025). A review of 13 studies plus 1 abstract on massive weight loss found mid-cheek volume loss and central neck laxity (Jafar et al., 2024), and a review of 23 articles said GLP-1 drugs cause changes "resembling advanced aging" while calling its conclusions "limited by study biases" (Daneshgaran et al., 2025).

Sources disagree on whether the drug itself matters. Cleveland Clinic says Ozempic face "isn't a side effect of the medication itself" but of rapid weight loss, while the AAD calls it "partly caused by rapid weight loss" and adds that "GLP-1 drugs affect your collagen and muscles, along with your fat cells." A 2026 review found that "direct GLP-1RA effects on dermal cells remain preclinical" (Karlin et al., 2026), and the closest human tissue data, from 40 post-bariatric vs 40 never-obese women, showed depleted collagen but undamaged elastic fibers (Orpheu et al., 2010). Go deeper with how to fix Ozempic face, dermal fillers for Ozempic face, Mounjaro face, Ozempic neck, loose skin after weight loss and stretch marks after weight loss. Evidence: Early / preliminary.

Can GLP-1 drugs cause acne or sweating?

Both are on the AAD's list of effects patients report, but neither has been confirmed in trials. The AAD describes "acne breakouts due to hormone changes" and excessive sweating (AAD).

A 2024 meta-analysis covering 45 articles on 6 GLP-1 drugs found no conclusive acne side effects (Ogunremi et al., 2024). The authors suggest weight-loss-related hormonal changes as a more likely explanation for acne some patients report, which is their hypothesis. Reader reports go both ways: some people with PCOS describe hormonal acne flaring after switching to tirzepatide, and others say it cleared.

For sweating, a FAERS analysis of 6 GLP-1 drugs, including tirzepatide, found hyperhidrosis (excessive sweating) among the 5 most common skin reactions reported, alongside eczematous reactions, itching, drug eruptions and hair loss (Daniel et al., 2025). Type 2 diabetes use had higher hyperhidrosis and hair loss rates than weight-management use. These are reporting signals, not rates. The AAD suggests gentle, alcohol-free acne products, no picking, and antiperspirant. Evidence: Limited.

Can GLP-1 drugs improve psoriasis or hidradenitis?

Possibly, but results disagree. Small trials show psoriasis improvement, while a liraglutide trial found no change and a large cohort linked GLP-1 drugs to more new psoriasis cases.

The AAD says some patients see less psoriasis itch and scaling, and fewer HS flares with less drainage, with HS patients who have obesity or type 2 diabetes benefiting most. Its quoted dermatologist adds, "We only have early data right now." PASI (Psoriasis Area and Severity Index) is a score of psoriasis extent and severity.

Tirzepatide plus a biologic: a randomized, open-label, 52-week trial at 72 US sites enrolled 274 people with psoriasis and overweight or obesity. At week 36, 40.6% on ixekizumab plus tirzepatide reached PASI 100 (complete clearance) vs 29.0% on ixekizumab alone (P=.04) (Lebwohl et al., 2026). Lilly makes both drugs and sponsored the trial; tirzepatide wasn't tested alone.
Semaglutide: an open-label RCT of 31 people with obesity, type 2 diabetes and psoriasis ran 12 weeks on top of metformin. Median PASI fell from 21 to 10 (p=.002) (Petković-Dabić et al., 2025). An uncontrolled 6-month cohort of 43 people without diabetes reported PASI down 48%, tracking superficial fat loss (r=0.89) (Nicolau et al., 2026).
Liraglutide: a 20-person, 8-week RCT found no significant PASI change vs placebo (−2.6 vs −1.3, P=.228) despite more weight loss (Faurschou et al., 2015).
Large cohort: a TriNetX target-trial emulation matched 169,630 people with type 2 diabetes per group for up to 4 years. Starting a GLP-1 drug was linked to more new psoriasis than starting a DPP-4 inhibitor (HR 1.19), and less pemphigus and bullous pemphigoid (Chiang et al., 2026). It's observational, and the comparator drug has its own skin associations.

A National Psoriasis Foundation primer notes PASI reductions of about 40% to 80%, but most studies had 7 to 48 patients, ran 6 months or less and lacked a control group (Sheth et al., 2026). For HS, a Danish cohort of 12,581 patients saw surgeries and systemic drug use fall after GLP-1 starts, but "comparable declines were observed among matched non-initiators" (Nielsen et al., 2026). Evidence: Mixed / contested.

What's the best GLP-1 skin care routine?

The AAD's GLP-1 skin care advice is basic: a gentle cleanser, a moisturizer with ceramides and antioxidants applied to damp skin over the whole body, and broad-spectrum, water-resistant SPF 30+ (AAD). Retinoids are an option, but the AAD warns they may cause irritation and flaking on dry skin.

Two long questions people ask search engines are how to build a skin care routine on a GLP-1 and which body washes help dry or sensitive skin. No specific cleanser or body wash has been tested in GLP-1 users. The AAD doesn't assign its tips to morning or night; the split below is ours, and none of the steps has been studied in GLP-1 users. For general product order, see our AM and PM skincare routine order.

AM

Gentle cleanser. AAD tip for GLP-1 users.
Moisturizer with ceramides and antioxidants, applied to damp skin.
Broad-spectrum, water-resistant SPF 30+, plus shade and protective clothing.
Acne-prone? Gentle, alcohol-free acne products; don't pick.

PM

Gentle cleanser.
Retinoid, optional. The AAD says to consider retinoids, but on dry skin they may cause irritation and flaking.
Ceramide and antioxidant moisturizer on damp skin.

Body & environment

Moisturize the whole body, including cuticles, on damp skin after bathing.
Humidifier, cleaned regularly, and plenty of fluids.
Keep skin folds clean and dry, since loose folds can cause rashes where skin touches skin.
Antiperspirant for excessive sweating.
Injection-site irritation that doesn't improve: ask the prescribing doctor for injection tips.

Our skincare routine order guide explains layering in general, and skin barrier basics covers why ceramides and damp-skin application matter. Evidence: Early / preliminary.

Do "GLP-1 skincare" products work?

No product sold as "GLP-1 skincare" contains a GLP-1 drug, and as of October 2026 only 2 small, industry-linked studies have tested topicals in GLP-1 users. Cleveland Clinic says GLP-1 "patches" "don't contain GLP-1 medication and have dubious effects."

Until 2026, no topical had been tested in GLP-1 users. Two studies changed that:

Volumizing cream: an open-label, single-arm study enrolled 33 adults with rapid weight loss, mostly on GLP-1/GIP drugs, and 29 completed 12 weeks (Nguyen et al., 2026). Wrinkle severity fell 20.7%, hydration rose 21.8% and water loss through the skin fell 12.7%. With no control group, the product can't be separated from time or plain moisturizing; funding wasn't stated, and the senior author consults for companies including Lilly and Galderma.
Antioxidant regimen ± ultrasound: a double-blind, randomized split-face and neck study of 25 GLP-1 users (mean age 53.4) ran 12 weeks (Moradi et al., 2026). After 4 weeks of the topical alone, laxity fell 16% vs no significant change on the placebo side; after one focused-ultrasound session on both sides, laxity was down 44% by week 12. Participants lost only an average 3.7 lb, and two authors are employees of the maker.

No peptide product has been tested in GLP-1 users. Our peptide ingredients ranked by evidence shows what peptides have shown in other groups, and peptides for loose skin explains what topicals can't fix.

GLP-1 skincare label decoder: claim vs what is tested
Feature	What the label implies	What has actually been tested
"GLP-1 skincare" or "for GLP-1 users"	Works with or through GLP-1 drugs	A marketing category. No product contains the drug.
"GLP-1 patch"	Delivers GLP-1 through the skin	Cleveland Clinic: patches don't contain GLP-1 medication and have dubious effects.
"Restores lost volume"	Replaces facial fat lost with weight	One open-label cream study, 29 completers, no control group (Nguyen 2026).
"Tightens laxity"	Reverses loose skin	One split-face study of 25 people, little weight lost during it, 2 maker employees as authors (Moradi 2026).
"Peptide complex"	Peptides repair GLP-1 skin changes	No peptide product tested in GLP-1 users.
"Clinically tested"	Shown to work in GLP-1 users	Only 2 studies exist in this group. Check n, control group and funder.
"Barrier repair" or "hydrating"	Fixes GLP-1 dry skin	Matches AAD moisturizer advice in general; not tested in GLP-1 users.

Bottom line: Treat GLP-1 skincare claims as untested unless the brand names a study in GLP-1 users with a control group.

Evidence: Early / preliminary.

Partly: both labels tie GLP-1 hair loss to weight reduction, the same driver as facial volume loss. A 2026 meta-analysis of 9 studies (7 RCTs) and 4,114 users found a pooled rate of 3.9% and a relative risk of 3.25 vs placebo, with no competing interests reported (Cheng et al., 2026), and a review describes it mainly as telogen effluvium, a temporary shedding pattern "potentially linked to rapid weight loss" (Burke et al., 2025). On Zepbound, hair loss affected 7.1% of women vs 0.5% of men (Zepbound label), and the AAD page quotes a dermatologist recommending a standard daily multivitamin. See our Ozempic hair loss guide. Evidence: Moderate.

Where the evidence stops

No faces in GLP-1 trials. Facial volume data come from 1 retrospective study of 20 people with mixed prescriptions.
No data on dry skin. The AAD's explanation hasn't been tested, and no study measured skin hydration in GLP-1 users.
No direct dermal studies in humans. Collagen effects of the drugs themselves remain preclinical.
Psoriasis needs bigger RCTs. Most studies are small, short and uncontrolled, and one cohort points the other way.
Filler reactions are case reports only. Two 2026 reports described nodules in old filler after starting compounded tirzepatide (Luke et al., 2026; Moore et al., 2026), and a response letter noted infection or biofilm wasn't excluded (Pitak-Arnnop et al., 2026). A 46-year-old's facial swelling after HA filler worsened after starting Ozempic and resolved with hyaluronidase (de Oliveira Ciaramicolo et al., 2024).
Skincare data are thin. Two small, industry-linked studies, and no peptide study in GLP-1 users.

What this does and doesn't prove
Feature	Does show	Doesn't prove
Drug labels, STEP UP, Meng 2023	Rates of dysesthesia, rash and injection-site reactions vs placebo; more reactions at higher tirzepatide doses	Why they happen, or how long they last
FAERS studies	Which skin events get reported, and when	That the drug caused them, or how often they happen
Sharma 2025 imaging study	Midface volume fell about 7% per 10 kg in 20 people	That the drug harms faces beyond weight loss
Psoriasis and HS studies	Some patients improved in small or add-on trials	That GLP-1 drugs treat psoriasis or HS on their own
Topical studies in GLP-1 users	Measurable skin changes in 29 and 25 people	That a product beats basic moisturizer and time

FAQ

Does Ozempic make your skin dry?